Research across Plasma cell dyscrasias
Related studies from across the Plasma cell dyscrasias family.
Lumbar Fractures as a Rare First Sign of Waldenström Macroglobulinemia
Rare Bone Fractures Linked to Waldenström Macroglobulinemia Identified
A systematic review found only 12 published cases of Waldenström macroglobulinemia first appearing as lumbar vertebral fractures.
New data identifies rare cases of lumbar vertebral fractures in patients with Waldenström macroglobulinemia, helping doctors distinguish the…
Diverse expansion methods and automated platforms offer pathways to scalable CAR-T cell manufacturing
New manufacturing methods aim to scale CAR-T cell therapy production
This narrative review examines ex vivo T-cell expansion techniques for CAR-T therapy in B-cell malignancies and multiple myeloma. It identif…
New manufacturing technologies and automated platforms aim to overcome hurdles in scaling CAR-T cell therapy for patients with blood cancers…
Intensified follow-up for MGUS leads to 27-fold increase in smoldering MM detection
Notifying People About a Precursor Blood Condition Finds Cancer Earlier
This randomized trial of 3541 individuals with monoclonal gammopathy (MGUS) in Iceland found that intensified follow-up significantly increa…
Telling people they have a blood cancer precursor led to far more early detection, without added anxiety.
Selinexor serves as an oral selective inhibitor of nuclear export for relapsed refractory multiple myeloma
Selinexor offers a new option for relapsed multiple myeloma
This narrative review examines the efficacy and adverse event management of selinexor in patients with relapsed or refractory multiple myelo…
Selinexor is showing potential for patients with relapsed or refractory multiple myeloma, though it can cause side effects like low blood co…
Circulating tumor DNA correlates with increased risk of aggressive disease progression and reduced overall survival
Circulating tumor DNA levels predict survival in multiple myeloma patients
This meta-analysis of 948 patients with multiple myeloma indicates that circulating tumor DNA (ctDNA) is associated with a higher risk of ag…
Detecting specific DNA fragments from tumors can help doctors identify patients with multiple myeloma who may face a more aggressive disease…
Spatial oligonucleotide immuno-reprogramming model provides a conceptual research framework for multiple myeloma study
New Research Framework Explores Oligonucleotides for Multiple Myeloma Treatment
This narrative review describes the Spatial oligonucleotide immuno-reprogramming model (SOIRM) as a conceptual and testable research framewo…
A new conceptual framework called SOIRM explores how spatially targeted oligonucleotides might one day help treat multiple myeloma.
Bispecific antibody therapy achieves 65.54% objective response rate in relapsed or refractory multiple myeloma
New bispecific antibodies show promise for relapsed multiple myeloma
This meta-analysis of 4,045 patients evaluates GPRC5D and BCMA targeted bispecific antibodies for relapsed or refractory multiple myeloma. T…
New bispecific antibody treatments show a 65.54% response rate for patients with relapsed or refractory multiple myeloma.
D-dimer elevated in high-risk multiple myeloma with pooled SMD of 1.60
D-dimer levels higher in high-risk multiple myeloma patients
This meta-analysis examined plasma D-dimer levels in patients with multiple myeloma, comparing high-risk groups (advanced ISS stage, venous …
A new analysis finds D-dimer levels are much higher in multiple myeloma patients at high risk for complications. This simple blood test coul…
Mezigdomide plus carfilzomib and dexamethasone improves progression-free survival to 18.0 months in multiple myeloma
Trial shows mezigdomide improves progression-free survival in multiple myeloma
This Phase 3 randomized controlled trial of 479 adult patients with measurable multiple myeloma found that mezigdomide plus carfilzomib and …
A new treatment combination involving mezigdomide and carfilzomib significantly extended the time patients lived without their cancer progre…
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
Daratumumab improves progression-free survival in patients with cytogenetically high-risk multiple myeloma
Daratumumab shows significant progress for high risk multiple myeloma
This meta-analysis evaluated the impact of daratumumab on progression-free survival in patients with cytogenetically high-risk multiple myel…
A new analysis shows that the drug daratumumab significantly slows the progression of high risk multiple myeloma in patients.
D-VRd ranks highest for progression-free survival among anti-CD38 regimens in transplant-ineligible multiple myeloma
New data ranks best treatments for transplant-ineligible multiple myeloma
This network meta-analysis of 6 trials involving 3162 patients evaluated various treatment nodes for transplant-ineligible newly diagnosed m…
A large review of 3,162 patients reveals which combinations of drugs work best to keep multiple myeloma from progressing.